HRMY enters the back half of August with a fresh analyst endorsement pulling in one direction and a notably heavy put/call ratio pulling in the other — two signals that don't obviously agree.
The most concrete development this week came from the Street. Wolfe Research initiated coverage this morning with an Outperform rating and a $60 price target — roughly 54% above Tuesday's close of $38.95. That's a meaningful opening bid, well above even the bulls in the existing coverage universe. The rest of the Street is broadly constructive: five buy-equivalent ratings, with Needham lifting its target to $50 and Mizuho nudging to $51 after the August 4 earnings beat. The dissenters are Truist and Deutsche Bank, both holding at Hold with targets in the low-to-mid $30s, reflecting concern about how long WAKIX's growth runway stays open before patent risk and competition constrain it. The consensus mean target of $47.36 implies roughly 22% upside from current levels, though Wolfe's $60 is a significant outlier pulling that average higher. On valuation, the stock trades at a P/E of about 6.2x and EV/EBITDA near 5x — multiples that have compressed modestly over the past month and sit well below typical specialty pharma levels, which underpins the bull case on value grounds.
Short sellers are stepping back. SI has fallen roughly 13% over the past month to 7.1% of the free float — still a real position, but the direction of travel is clearly downward, with the most recent daily reading dropping another 5.6%. The lending market tells the same story: borrow costs run at just 0.55%, firmly in low territory, and availability is extremely loose at 959% — meaning there are nearly ten shares available to borrow for every one already shorted. That ratio is at its highest point of the past year, up from a tighter 624% in late July, suggesting the supply of shares to lend is growing just as short demand is falling. The ORTEX short score has also drifted lower this week, easing from around 52 to just under 50, consistent with a position that is quietly being unwound rather than rebuilt.
Options positioning is the contrarian note in this setup. The put/call ratio has jumped to 2.88 — nearly at its 52-week high of 2.89 — and well above the 20-day average of 2.22. The z-score of roughly one standard deviation above the mean is not extreme, but the absolute level of the ratio is unusually heavy, suggesting there is meaningful demand for downside protection even as short sellers reduce outright positions. Interestingly, the PCR was closer to 1.0 through late July and early August, then spiked above 2.5 around August 5 — right after earnings — and has stayed elevated since. That shift coincides with the stock's 10% one-month gain; it reads less like fresh bearishness and more like holders locking in gains through put protection.
The earnings backdrop gives some context. The August 4 print produced a 7.4% one-day move and an 11% five-day follow-through — the stock's strongest quarterly reaction in recent history. The prior quarter produced a near-flat one-day result before recovering 7.7% over the following week. The next event is slated for October 27, leaving about two months for the current positioning to evolve. EPS momentum factor scores rank in the 89th and 90th percentile on 30- and 90-day bases, and the forward EPS growth estimate is ranked at the 100th percentile across the universe — reflecting aggressive upward revisions that have driven much of the recent re-rating.
Institutional flows add a modest constructive tilt. Fidelity added 416,000 shares as of July 31, American Century added 434,000, and Dimensional added 317,000 — all meaningful relative to the stock's free float. BlackRock remains the largest holder at 12.2% of shares. Insider data is stale (last reported May 1) and not material to the current setup.
The tension heading into October's print is clear: Wolfe's arrival at a $60 target frames the bull case boldly, short sellers are reducing exposure, and institutional buyers are adding — but options traders are hedging at near-record put intensity, suggesting at least some of the recent 10% gain is being held cautiously rather than confidently.
See the live data behind this article on ORTEX.
Open HRMY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
